170 related articles for article (PubMed ID: 34603326)
1. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
Front Immunol; 2021; 12():740517. PubMed ID: 34603326
[TBL] [Abstract][Full Text] [Related]
2. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Analysis of the Safety Profile of Intravenous Immunoglobulin in 1176 Patients Receiving Home Infusion Therapy.
Souayah N; Pahwa A; Burawski L; Opila T; Sander HW
J Clin Neuromuscul Dis; 2018 Jun; 19(4):181-195. PubMed ID: 29794573
[TBL] [Abstract][Full Text] [Related]
4. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
5. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
[TBL] [Abstract][Full Text] [Related]
7. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
8. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
Nosadini M; Mohammad SS; Suppiej A; Sartori S; Dale RC;
Dev Med Child Neurol; 2016 Nov; 58(11):1180-1192. PubMed ID: 27242065
[TBL] [Abstract][Full Text] [Related]
10. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
11. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
12. Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.
Waheed W; Ayer GA; Jadoo CL; Badger GJ; Aboukhatwa M; Brannagan TH; Tandan R
Muscle Nerve; 2019 Nov; 60(5):528-537. PubMed ID: 31443119
[TBL] [Abstract][Full Text] [Related]
13. [Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].
Hatake S; Shimizu F; Honda M; Takahashi S; Koga M; Kimura K; Kanda T
Rinsho Shinkeigaku; 2022 Apr; 62(4):267-271. PubMed ID: 35354723
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
Sapir T; Blank M; Shoenfeld Y
Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
[TBL] [Abstract][Full Text] [Related]
15. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
[TBL] [Abstract][Full Text] [Related]
16. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
[TBL] [Abstract][Full Text] [Related]
17. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
18. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions.
Piguet D; Tosi C; Lüthi JM; Andresen I; Juge O;
Clin Exp Immunol; 2008 Apr; 152(1):45-9. PubMed ID: 18241226
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
Dalakas MC
JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases.
Graf J; Ingwersen J; Lepka K; Albrecht P; Hartung HP; Ringelstein M; Aktas O
Acta Neurol Scand; 2019 Oct; 140(4):290-295. PubMed ID: 31269227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
